A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

Phase 1 Completed 33 enrolled Pfizer

RandomizedCrossoverDouble-blindBasic science

Summary

A phase 1, 6-sequence, 3-period, subject- and investigator blinded and sponsor-open, crossover study in healthy volunteers to evaluate the PF-06700841 effect on QTc interval. Each subject randomized will receive placebo, PF-06700841 200 mg and moxifloxacin (open label) in one of the 6 sequences. Moxifloxacin is positive control to demonstrate the study sensitivity and PF-06700841 effect on QTc will be assessed by concentration-QT analysis

Timeline

Start: 2018-09-05
Primary completion: 2019-02-06
Completion: 2019-02-06

Publications

Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1447-1456. doi: 10.1002/cpdd.1163. Epub 2022 Aug 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brepocitinib	Small molecule	200 mg	Oral
Subject	Moxifloxacin	Small molecule	400 mg	Oral

Indications

No indication recorded.